James Parsons Acquires 10,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director James Parsons purchased 10,000 shares of the company’s stock in a transaction on Wednesday, March 11th. The stock was acquired at an average price of $1.03 per share, with a total value of $10,300.00. Following the purchase, the director owned 41,849 shares of the company’s stock, valued at approximately $43,104.47. This represents a 31.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Oncolytics Biotech Trading Up 2.3%

Shares of NASDAQ ONCY opened at $0.98 on Friday. The stock has a market cap of $104.45 million, a P/E ratio of -3.51 and a beta of 0.92. Oncolytics Biotech Inc. has a 12-month low of $0.33 and a 12-month high of $1.51. The business’s fifty day simple moving average is $1.01 and its 200-day simple moving average is $1.08.

Institutional Trading of Oncolytics Biotech

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Oncolytics Biotech in the fourth quarter valued at $68,000. Connective Capital Management LLC acquired a new position in shares of Oncolytics Biotech during the 4th quarter worth about $131,000. XTX Topco Ltd purchased a new position in shares of Oncolytics Biotech in the 4th quarter valued at about $69,000. Blair William & Co. IL purchased a new position in shares of Oncolytics Biotech in the 4th quarter valued at about $28,000. Finally, Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Oncolytics Biotech during the 4th quarter worth about $29,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ONCY shares. HC Wainwright lifted their price objective on Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. Finally, Wall Street Zen cut shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.